Peringatan Keamanan

The primary anticipated complication of overdosage would consist of bone marrow suppression.

Topotecan

DB01030

small molecule approved investigational

Deskripsi

An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Struktur Molekul 2D

Berat 421.4458
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 2-3 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Topotecan undergoes a reversible pH dependent hydrolysis of its lactone moiety; it is the lactone form that is pharmacologically active.

Rute Eliminasi

Renal clearance is an important determinant of topotecan elimination. In a mass balance/excretion study in 4 patients with solid tumors, the overall recovery of total topotecan and its N-desmethyl metabolite in urine and feces over 9 days averaged 73.4 ± 2.3% of the administered IV dose. Fecal elimination of total topotecan accounted for 9 ± 3.6% while fecal elimination of N-desmethyl topotecan was 1.7 ± 0.6%.

Interaksi Makanan

1 Data
  • 1. Take with or without food.

Interaksi Obat

1478 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Topotecan.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Topotecan.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Topotecan.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Topotecan.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Topotecan.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Topotecan.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Topotecan.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Topotecan.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Topotecan.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Topotecan.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Topotecan.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Topotecan.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Topotecan.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Topotecan.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Topotecan.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Topotecan.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Topotecan.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Topotecan.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Topotecan.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Topotecan.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Topotecan.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Topotecan.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Topotecan.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Topotecan.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Topotecan.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Topotecan.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Topotecan.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Topotecan.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Topotecan.
Cladribine Topotecan may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Topotecan.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Topotecan.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Topotecan.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Topotecan.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Topotecan.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Topotecan.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Topotecan.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Topotecan.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Topotecan.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Topotecan.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Topotecan.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Topotecan.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Topotecan.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Topotecan.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Topotecan.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Topotecan.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Topotecan.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Topotecan.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Topotecan.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Topotecan.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Topotecan.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Topotecan.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Topotecan.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Topotecan.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Topotecan.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Topotecan.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Topotecan.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Topotecan.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Topotecan.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Topotecan.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Topotecan.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Topotecan.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Topotecan.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Topotecan.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Topotecan.
Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Topotecan.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Topotecan.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Topotecan.
Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Topotecan.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Topotecan.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Topotecan.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Topotecan.
Mercaptopurine The risk or severity of adverse effects can be increased when Topotecan is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Topotecan is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Topotecan is combined with Melphalan.
Fludarabine The risk or severity of adverse effects can be increased when Topotecan is combined with Fludarabine.
Flucytosine The risk or severity of adverse effects can be increased when Topotecan is combined with Flucytosine.
Capecitabine The risk or severity of adverse effects can be increased when Topotecan is combined with Capecitabine.
Procarbazine The risk or severity of adverse effects can be increased when Topotecan is combined with Procarbazine.
Idarubicin The risk or severity of adverse effects can be increased when Topotecan is combined with Idarubicin.
Lomustine The risk or severity of adverse effects can be increased when Topotecan is combined with Lomustine.
Eculizumab The risk or severity of adverse effects can be increased when Topotecan is combined with Eculizumab.
Decitabine The risk or severity of adverse effects can be increased when Topotecan is combined with Decitabine.
Nelarabine The risk or severity of adverse effects can be increased when Topotecan is combined with Nelarabine.
Abatacept The risk or severity of adverse effects can be increased when Topotecan is combined with Abatacept.
Corticotropin The risk or severity of adverse effects can be increased when Topotecan is combined with Corticotropin.
Cortisone acetate The risk or severity of adverse effects can be increased when Topotecan is combined with Cortisone acetate.
Paramethasone The risk or severity of adverse effects can be increased when Topotecan is combined with Paramethasone.
Ciclesonide The risk or severity of adverse effects can be increased when Topotecan is combined with Ciclesonide.
Stepronin The risk or severity of adverse effects can be increased when Topotecan is combined with Stepronin.
Castanospermine The risk or severity of adverse effects can be increased when Topotecan is combined with Castanospermine.
Vorinostat The risk or severity of adverse effects can be increased when Topotecan is combined with Vorinostat.
2-Methoxyethanol The risk or severity of adverse effects can be increased when Topotecan is combined with 2-Methoxyethanol.
Brequinar The risk or severity of adverse effects can be increased when Topotecan is combined with Brequinar.
Aldosterone The risk or severity of adverse effects can be increased when Topotecan is combined with Aldosterone.
Pirfenidone The risk or severity of adverse effects can be increased when Topotecan is combined with Pirfenidone.
Afelimomab The risk or severity of adverse effects can be increased when Topotecan is combined with Afelimomab.
Interferon alfa The risk or severity of adverse effects can be increased when Topotecan is combined with Interferon alfa.
Glatiramer The risk or severity of adverse effects can be increased when Topotecan is combined with Glatiramer.
Briakinumab The risk or severity of adverse effects can be increased when Topotecan is combined with Briakinumab.

Target Protein

DNA topoisomerase 1 TOP1
DNA
DNA topoisomerase I, mitochondrial TOP1MT

Referensi & Sumber

Synthesis reference: Venkata Raghavendra Palle, Sekhar Nariyam, Lankeshwara Matti, "PROCESS FOR PREPARING TOPOTECAN." U.S. Patent US20070149783, issued June 28, 2007.
Artikel (PubMed)
  • PMID: 9885371
    Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C: Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology. 1999;56(1):1-12.
  • PMID: 8853931
    Herben VM, ten Bokkel Huinink WW, Beijnen JH: Clinical pharmacokinetics of topotecan. Clin Pharmacokinet. 1996 Aug;31(2):85-102.
  • PMID: 9122737
    Dennis MJ, Beijnen JH, Grochow LB, van Warmerdam LJ: An overview of the clinical pharmacology of topotecan. Semin Oncol. 1997 Feb;24(1 Suppl 5):S5-12-S5-18.

Contoh Produk & Brand

Produk: 63 • International brands: 0
Produk
  • Hycamtin
    Capsule • 0.25 mg/1 • Oral • US • Approved
  • Hycamtin
    Capsule • 1 mg/1 • Oral • US • Approved
  • Hycamtin
    Capsule • 0.25 mg/1 • Oral • US • Approved
  • Hycamtin
    Capsule • 1 mg/1 • Oral • US • Approved
  • Hycamtin
    Injection, powder, lyophilized, for solution • 4 mg/4mL • Intravenous • US • Approved
  • Hycamtin
    Injection, powder, lyophilized, for solution • 4 mg/4mL • Intravenous • US • Approved
  • Hycamtin
    Injection, powder, lyophilized, for solution • 4 mg/4mL • Intravenous • US • Approved
  • Hycamtin
    Capsule • .25 mg/1 • Oral • US • Approved
Menampilkan 8 dari 63 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul